Literature DB >> 9894566

In vitro modulation of activation antigens on human lymphocytes by beta-estradiol.

L Komlos1, Z Zahavi, D Dicker, D Luria, H Salman, I Zahavi.   

Abstract

PROBLEM: The possible in vitro immunomodulating effect of beta-estradiol on phytohemagglutinin-stimulated human lymphocyte cultures was studied. METHOD OF STUDY: Lymphocyte cultures from 12 healthy men and women aged 25-35 years were set up for 12 hr in the presence and in the absence of beta-estradiol, and the expression of the activation markers CD25, CD69, and CD71 was examined by flow cytometric analysis with specific fluorescent conjugated antibodies.
RESULTS: Although the number of cases is small, in 10 of 12 cases in the presence of beta-estradiol in two different concentrations, a significantly decreased expression of CD69 could be observed. A slight decrease could also be observed for the Interleukin-2 receptor expression; however, the difference, in the presence or absence of beta-estradiol, was not significant.
CONCLUSIONS: The results suggest that in vitro addition of beta-estradiol can inhibit, to a certain degree, specific activation markers on phytohemagglutinin-stimulated lymphocytes from young men and women. The present study could not define the role of sex differences because of the small number of samples. A comparison between men and women at various ages in a greater number of cases, as well as studies on activation markers after treatments with estrogens, would be useful.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9894566     DOI: 10.1111/j.1600-0897.1998.tb00428.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  2 in total

1.  Immunomodulatory effects of estrogen and progesterone replacement in a nonhuman primate model.

Authors:  Roberta Attanasio; Deborah A Gust; Mark E Wilson; Tracy Meeker; Thomas P Gordon
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

2.  Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes.

Authors:  Yijun Jia; Lei Xu; Qing Lin; Mingjie Zhu; Longlong Ding; Kejin Wu; Yunshu Lu
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.